Read full article: A phase 2 trial tested TIL therapy in metastatic uveal melanoma Response rates were 37% with reactive TIL vs. 0% without Responses lasted a median of 17.3 months A pre-surgery biopsy score, UMIS, helped predict who responded Researchers are now [...]
Read full article: Uveal melanoma's distinct biology has made it resist systemic treatment HLA-A*02:01–negative patients have historically had limited options Past choices: liver-directed therapy, off-label combos, or clinical trials OptimUM-02 tested darovasertib plus crizotinib vs. investigator's choice More emerging options are making treatment [...]
Read full article: Jefferson researchers tested defactinib plus avutometinib in 12 MUM patients The drug pairing was selected using "synthetic lethality analysis" Tumors didn't shrink: six stayed stable and six progressed The enzyme ALDH1A3 rose in several patients whose disease progressed The findings [...]
Read full article: The study: Moffitt researchers analyzed 60 advanced melanoma patients from four clinical trials to understand why TIL immunotherapy helps some patients but not others. Cell quality matters: Infusions with more CD8+ T cells and "stem-like memory" T cells were linked [...]
Read full article: Multidisciplinary care is improving the patient experience and treatment planning. Liquid biopsies may help detect and monitor uveal melanoma with a simple blood test. New vision-preserving approaches are improving quality of life after treatment. Artificial intelligence may help identify suspicious [...]
Read full article: DYP688 is a new targeted therapy developed specifically for GNAQ- and GNA11-mutated melanomas. The treatment delivers medicine directly to PMEL-positive melanoma cells. Researchers observed tumor shrinkage or disease control in many participants. Most treatment-related side effects were manageable and did [...]
Read full article: Researchers completed a successful Phase I safety trial of the investigational oral drug 7HP349. The study found the medication was well tolerated, with no treatment-related serious adverse events reported. The therapy is designed to strengthen the body's immune response rather [...]
Read full article: Researchers identified BAP1 gene abnormalities as a strong predictor of metastatic uveal melanoma. Combining BAP1 changes with chromosome 1 alterations improved the accuracy of metastasis risk prediction. The new classification system successfully separated patients into four distinct metastatic risk groups. [...]
Read full article: A Cure In Sight earned Charity Navigator's highest 4-Star Rating for 2026. The rating recognizes excellence in financial responsibility, accountability, and transparency. Charity Navigator has helped donors evaluate nonprofit organizations since 2001. Every donation supports programs that directly benefit patients, [...]
Read full article: Mike's vision loss led to the diagnosis of a rare eye cancer called uveal melanoma. Routine follow-up imaging detected metastatic disease in his liver before symptoms became severe. Participation in a clinical trial resulted in the complete disappearance of his [...]
